Dishman Carbogen Amcis Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/oig7tcileeke8pzv67t2u10g.pdf

Key Takeaways


The Revenue Shortfall: What Broke and Why

Dalal: "It was obviously an unusual quarter for us. But what we saw was that the revenues that we could accrue in terms of the development work, especially in August and September, those were quite low, as compared to what our expectation was. And this was because certain orders, which we were expecting could be completed by the end of September, they were not. And because of the customer requirements, some of them were also deferred to the next year because of the funding situation."

Margin Impact: Fixed Costs Meet Falling Revenue

Dalal: "Since most of our expenses are fixed in nature, the decline in the revenue would have a significant impact on the EBITDA. And on the flip side, as the revenues increase in the future, that should also have a significant positive impact on the EBITDA."

The H2 Recovery Bet

Fritschi: "ur consideration is if AI development continues slowing down, some shift of venture capital into pharmaceutical industry is expected. This means more new API development projects will be funded, what leads into an increased demand of CDMO services. So, let's see what happens, but we are rather optimistic here."

Tech Transfers and Bavla: The Medium-Term Pivot

Fritschi: "his specific tech transfer I was referring to is from a big pharma. And it's quite significant, as Harshil mentioned, something between CHF 15 and 2 crore revenues to be expected once it's transferred. So, the tech transfer itself follows the normal procedure. There's nothing to be expected as a surprise at the moment."

Strategic Shifts: Big Phrma, Early Phase, and Commercial Expansion

Dalal: "he business is dependent upon one, the molecules coming for development. And historically, what we have been targeting are the small molecules, so essentially the biotech company. But now as Stephan alluded, we are also now trying to target the big pharma also on the development side, especially the molecules in Phase III as well, with a very clear idea that we could do the commercial manufacturing out of the India sites."

Balance Sheet, Funding, and the Family Transaction


Guidance & Commitments

CommitmentSpecificsTimeline
Full-year FY27 revenueDo not expect growth over last year; expect to get closer to that number by year-endFY27
Full-year FY27 operating profitWill be lower vs. last year; may not match last year's operating marginFY27
Full-year FY27 CapexClose to ~₹200 crores, including maintenance Capex and SAP/digital transformationFY27
Bavla full-year revenueIn excess of ₹400–450 croresNext financial year (FY28)
Medium-term top-line growthAt least high-single-digit or double-digit growth; 10–12% yearly for FY28-29Medium term / FY28-29
Medium-term EBITDA marginIn excess of 20–21%FY28-29
ECB first tranche drawdownAt least close to ~₹5 crore; trying to complete before Christmas holidays, otherwise JanuaryQ4 FY27 or Q1 FY28
Interest cost reductionAs soon as ECB is deployed; most likely from Q4, otherwise Q1 next financial yearQ4 FY27 or Q1 FY28
Big pharma tech transfer validationValidation batches expected around March-AprilAround March-April
First Carbogen Amcis legacy product tech transferOn schedule for completion by end of this financial yearFY27
Second co-investment with Japanese innovatorExpected to go live, providing increased capacitiesNext financial year (FY28)

Key Metrics

MetricQ2 FY27
Revenue₹507 cr, 22% decline YoY
Cost of goods sold₹34 cr, ~7% of revenue, similar to last year
Employee expenses₹321 cr
Other expenses₹105 cr, 23% decline YoY
EBITDA₹46 cr
H1 FY27 EBITDA₹106 cr
Depreciation₹90 cr; H1 FY27: ₹181 cr
Finance cost₹40 cr
CDMO segment revenue₹388 cr, vs ₹509 cr in Q2 FY26
CDMO segment margin12.3%, vs 25% in Q2 FY26
Marketable Molecules segment revenue₹118 cr, vs ₹143 cr in Q2 FY26
CapEx$5.4 million; H1 FY27: $10.3 million
Full-year FY27 CapEx guidance~₹200 cr
Full-year FY27 revenue guidanceMight not see growth vs FY26, revised from high single-digit growth
Full-year FY27 consolidated EBITDA margin guidance15–16%
Development pipelineCHF 9.8 cr, up from CHF 8.9 cr in Q1 FY27
Late Phase III pipeline~13 molecules, up from 10 six months ago; one molecule commercialized in calendar year
Net debt (consolidated)~₹16.5 cr
Cash balance~₹1,000 cr
French facility revenueCHF 0.1 cr
French facility EBITDANegative CHF 0.17 cr
Bavla full-year revenue expectation (next financial year)In excess of ₹400–450 cr
Medium-term annual revenue growth expectationAt least high-single digit or double-digit
Medium-term EBITDA margin expectationIn excess of 20–21% for FY28-29
Expected quarterly interest cost post-ECB deployment₹20–25 cr, down from current ~₹40 cr
Annualized revenue potential from ongoing tech transfersRoughly CHF 2.5–3 cr (per management's ballpark assumption, stated as CHF 3 cr or CHF 25 to 3 cr)